Management of Adults With Diabetes and Cognitive Problems

Hopkins, Rachel; Shaver, Kristi; Weinstock, Ruth S.

doi:10.2337/ds16-0035

Cited by 52 publications

(50 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Они включают самоконтроль гликемии, здоровое питание, физическую активность, прием медикаментов по назначению врача, распознавание и купирование гипогликемии, гигиену нижних конечностей и т.д. [56]. При СД роль пациента не ограничивается исполнением врачебных предписаний, он фактически становится важным членом команды управления диабетом, что требует специального обучения.…”

Section: дисфункция церебральных сосудовunclassified

“…В ряде исследований получены данные о потенциальных положительных эффектах препаратов инсулина на когнитивные функции [20,56,63]. Считается, что инсулин уменьшает внутриклеточное содержание амилоида, способствует гипофосфорилированию, которое стабилизирует микротрубочки, способствуя полимеризации тубулина.…”

Section: препараты инсулинаunclassified

“…Факторы, которые следует учитывать при фармакотерапии инсулином, включают риск гипогликемии, стоимость, продолжительность действия и простоту использования. КН могут препятствовать самообслуживанию пациентов, связанному с использованием препаратов инсулина [56]. Важнейшим фактором в заместительной инсулинотерапии у пациентов с СД и КН считают режим его дозирования.…”

Section: препараты инсулинаunclassified

“…У пациентов с более выраженными КН или демен цией наиболее предпочтительно использование инсулина длительного действия при дозировках, которые не вызывают гипогликемии в сочетании с консервативными фиксированными дозами принимаемой пищи. Уменьшение дозировки инсулина может быть реализовано на основании количества потребляемой пищи (например, 50% рекомендуемой дозы инсулина, если фактическое потребление углеводов составило порядка 50% планируемого) [56].…”

Section: препараты инсулинаunclassified

See 3 more Smart Citations

Cognitive impairment in patients with type 2 diabetes mellitus: prevalence, pathogenetic mechanisms, the effect of antidiabetic drugs

et al. 2018

View full text Add to dashboard Cite

In recent years, a large amount of data has been accumulated on the relationship between cognitive impairment, dementia and diabetes mellitus. This article presents an overview of modern literature, including the definition of cognitive functions, the modern classification of cognitive impairment, pathogenetic mechanisms of diabetes mellitus influence on the development of cognitive impairment and dementia (neurogenesis, integrity of the blood-brain barrier, systemic inflammatory reactions, hyper- and hypoglycemia, insulin resistance, vascular dysfunction of the microvasculature and increase in glucocorticosteroids). The influence of anti-diabetic medications on cognitive functions has been examined in detail: insulin preparations, oral hypoglycemic agents of the biguanide group (metformin), thiazolidinediones (rosiglitazone and pioglitazone), sulfonylurea derivatives (glycazide, glipizide), a-glucosidase (acarbose) inhibitors, incretin-directed therapy (receptor agonists glucan-like peptide (exenatide and liraglutide) and inhibitors of dipeptidylpeptidase type 4 (sitagliptin, vildagliptin and alogliptin)), sodium glucose inhibitors cotransporter type 2. The data demonstrating a multidirectional effect on the cognitive functions of various antidiabetic drugs is presented, the possible influence on the rate of progression of cognitive impairment and the risk of dementia of intensive control of plasma glucose level in comparison with the standard decrease in patients with type 2 diabetes is analyzed.

show abstract

Section: дисфункция церебральных сосудовunclassified

Section: препараты инсулинаunclassified

See 2 more Smart Citations

Cognitive impairment in patients with type 2 diabetes mellitus: prevalence, pathogenetic mechanisms, the effect of antidiabetic drugs

et al. 2018

View full text Add to dashboard Cite

show abstract

“…To ameliorate this complication of cognitive dysfunction in diabetes several compounds like ghrelin, huperazine A, naringin, resveratrol, erythropoietin, dihydromyricetin, nicorandil, and geniposide showed improved memory in animal models of diabetes (Chen, Liu, Fang, & Liu, ; Liu et al, ; Ma et al, ; Mao et al, ; Tian et al, ; Wang et al, ; Yan et al, ; Zhu et al, ). Since last few years, antidiabetic drugs are being widely used to treat impaired cognition in diabetes but they suffer from the major disadvantage of being nonspecific in treatment (Hopkins, Shaver, & Weinstock, ).…”

Section: Introductionmentioning

confidence: 99%

Cognitive dysfunction: A growing link between diabetes and Alzheimer's disease

Jash

Gondaliya

Kirave

et al. 2019

Drug Development Research

View full text Add to dashboard Cite

Diabetes mellitus (DM) is a gradually rising metabolic disease which is currently affecting millions of people worldwide. Diabetes is associated with various complications like nephropathy, neuropathy, retinopathy, diabetic foot, cognitive impairment, and many more. Evidence suggests that cognitive dysfunction is a rising complication of diabetes which adversely affects the brain of patients suffering from diabetes. Age‐related memory impairment is a complication having its major effect on people suffering from diabetes and Alzheimer's. Patients suffering from diabetes are at two times higher risk of developing cognitive dysfunction as compared with normal individuals. Multiple factors which are involved in diabetes related complications are found to play a role in the development of neurodegeneration in Alzheimer's. The problem of insulin deficiency and insulin resistance is well reported in diabetes but there are many studies which suggest dysregulation of insulin levels as a reason behind the development of Alzheimer's. As the link between diabetes and Alzheimer disease (AD) is deepening, there is a need to understand the plausible tie‐ins between the two. Emerging role of major factors like insulin imbalance, advanced glycation end products and micro‐RNA's involved in diabetes and Alzheimer's have been discussed here. This review helps in understanding the plausible mechanism underlying the pathophysiology of amyloid beta (Aβ) plaque formation and tau hyperphosphorylation as well provides information about studies carried out in this area of research. The final thought is to enhance the scientific knowledge on this correlation and develop future therapeutics to treat the same.

show abstract

Effect of cognitive impairment on risk of death in Hispanic/Latino adults over the age of 50 residing in the United States with and without diabetes: Data from the Health and Retirement Study 1995–2014

Martínez

Dawson

et al. 2021

Alzheimer's & Dementia

View full text Add to dashboard Cite

Objective: To understand the relationship between mortality and cognitive function among older US Hispanic adults with and without diabetes.Methods: Data from the Health and Retirement Study (1995-2014) were analyzed.Cox proportional hazard models were used to estimate the association between mortality and cognitive function. Models were stratified by diabetes.Results: Four thousand thirteen older US Hispanic adults were included. Fully adjusted models for individuals with diabetes showed those with mild cognitive impairment (MCI; hazard ratio [HR]: 1.61; 95% confidence interval [CI]: 1.06, 2.45; P = .025) and dementia (HR: 2.14; 95% CI: 1.25, 3.67; P = .006) had increased mortality compared to normal cognition. Fully adjusted models for individuals without diabetes showed those

show abstract

Management of Adults With Diabetes and Cognitive Problems

Cited by 52 publications

References 48 publications

Cognitive impairment in patients with type 2 diabetes mellitus: prevalence, pathogenetic mechanisms, the effect of antidiabetic drugs

Cognitive impairment in patients with type 2 diabetes mellitus: prevalence, pathogenetic mechanisms, the effect of antidiabetic drugs

Cognitive dysfunction: A growing link between diabetes and Alzheimer's disease

Effect of cognitive impairment on risk of death in Hispanic/Latino adults over the age of 50 residing in the United States with and without diabetes: Data from the Health and Retirement Study 1995–2014

Contact Info

Product

Resources

About